Trials / Unknown
UnknownNCT00917839
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Cantonal Hospital of St. Gallen · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lamotrigine | 100 mg, once daily, 12 months |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-12-01
- Completion
- 2011-12-01
- First posted
- 2009-06-10
- Last updated
- 2009-06-10
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00917839. Inclusion in this directory is not an endorsement.